Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.
2.

Dramatic response in the dependency to transfusion after low doses of lenalidomide treatment in a 5q-syndrome patient: a case report.

Dogu MH, Sari I, Hacioglu S, Keskin A.

North Clin Istanb. 2015 Jan 24;1(3):191-193. doi: 10.14744/nci.2014.36036. eCollection 2014.

3.

Asthma and risk of myelodysplastic syndromes: a population-based cohort study.

Frederiksen H, Farkas DK, Horváth-Puhó E, Nørgaard JM, Nørgaard M, Sørensen HT.

Br J Cancer. 2017 Jan 3;116(1):100-102. doi: 10.1038/bjc.2016.389. Epub 2016 Nov 29.

PMID:
27898660
4.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF.

Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.

PMID:
27737891
5.

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF.

Cancer Res. 2016 Jun 15;76(12):3531-40. doi: 10.1158/0008-5472.CAN-15-1756. Epub 2016 Apr 6.

PMID:
27197154
6.

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.

Ding K, Fu R, Liu H, Nachnani DA, Shao ZH.

Oncol Lett. 2016 Apr;11(4):2347-2352. Epub 2016 Feb 23.

7.

A Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules.

Alzoman NZ.

J Chromatogr Sci. 2016 May-Jun;54(5):730-5. doi: 10.1093/chromsci/bmv247. Epub 2016 Feb 4.

PMID:
26850732
8.

The novel mechanism of lenalidomide activity.

Fink EC, Ebert BL.

Blood. 2015 Nov 19;126(21):2366-9. doi: 10.1182/blood-2015-07-567958. Epub 2015 Oct 5. Review.

9.

Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R.

Cancer Med. 2015 Dec;4(12):1789-97. doi: 10.1002/cam4.523. Epub 2015 Sep 17.

10.

Biology of the bone marrow microenvironment and myelodysplastic syndromes.

Rankin EB, Narla A, Park JK, Lin S, Sakamoto KM.

Mol Genet Metab. 2015 Sep-Oct;116(1-2):24-8. doi: 10.1016/j.ymgme.2015.07.004. Epub 2015 Jul 20. Review.

11.

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Petrou E, Mavrogeni S, Karali V, Kolovou G, Kyrtsonis MC, Sfikakis PP, Panayiotidis P.

Rev Bras Hematol Hemoter. 2015 Jul-Aug;37(4):252-8. doi: 10.1016/j.bjhh.2015.03.014. Epub 2015 May 19.

12.

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).

Butrym A, Lech-Maranda E, Patkowska E, Kumiega B, Bieniaszewska M, Mital A, Madry K, Torosian T, Wichary R, Rybka J, Warzocha K, Mazur G.

BMC Cancer. 2015 Jul 8;15:508. doi: 10.1186/s12885-015-1444-1.

13.

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL.

Nature. 2015 Jul 9;523(7559):183-8. doi: 10.1038/nature14610. Epub 2015 Jul 1.

14.

Expanding role of lenalidomide in hematologic malignancies.

Ghosh N, Grunwald MR, Fasan O, Bhutani M.

Cancer Manag Res. 2015 May 2;7:105-19. doi: 10.2147/CMAR.S81310. eCollection 2015. Review.

15.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF.

Blood Cancer J. 2015 Mar 13;5:e291. doi: 10.1038/bcj.2015.11.

16.

Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.

Pease DF, Ross JA, Poynter JN, Nguyen PL, Hirsch B, Cioc A, Roesler MA, Warlick ED.

Cancer Epidemiol. 2015 Apr;39(2):222-8. doi: 10.1016/j.canep.2015.01.006. Epub 2015 Feb 18.

17.

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.

Abou Zahr A, Saad Aldin E, Komrokji RS, Zeidan AM.

J Blood Med. 2014 Dec 22;6:1-16. doi: 10.2147/JBM.S50482. eCollection 2015. Review.

18.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

19.

Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.

McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF.

PLoS One. 2014 Dec 3;9(12):e114249. doi: 10.1371/journal.pone.0114249. eCollection 2014.

20.

Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS).

Uno H, Cronin AM, Wadleigh M, Schrag D, Abel GA.

Leuk Res. 2014 Dec;38(12):1420-4. doi: 10.1016/j.leukres.2014.09.011. Epub 2014 Sep 30.

Supplemental Content

Support Center